{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:31:20Z","timestamp":1761129080369},"reference-count":9,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,6,3]],"date-time":"2013-06-03T00:00:00Z","timestamp":1370217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>We investigated the effects of prophylactic nucleoside analogue treatment on <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> activation in patients with antibodies against core antigen (<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b+) patients undergoing immunosuppressive therapy. Patients (113), who were <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b+, with various autoimmune diseases, undergoing immunosuppressive therapy, were divided into two groups. The control group, not treated with antivirals, and the prophylactic group, treated with antiviral drugs. The two groups were evaluated for changes in serum biochemical marker (alanine aminotransferase <jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content>), virological marker (<jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content>) and for seroconversion. In the control group, the number of patients with an increase in <jats:styled-content style=\"fixed-case\">ALT<\/jats:styled-content> in patients with isolated <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b and <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b and antibodies against <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>g (<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b +) were five (20.0%) and one (2.8%), respectively (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.05). There were six cases (24.0%) with an increase in <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> in the isolated <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b+ subgroup and one case (2.8%) in <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b+\/<jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b+ subgroup (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). In the <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b+ only population, six patients (24.0%) in the control group had an increase in <jats:styled-content style=\"fixed-case\">HBV DNA<\/jats:styled-content> compared with none in the antiviral prophylactic group (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.05). One patient (4.0%) with <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b+ in the control group underwent an <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>g seroconversion when receiving immunosuppressive therapy for 18\u00a0months, while none in the antiviral prophylactic group underwent reversion to <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>g positivity (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.4949). Under immunosuppressive condition, the risk of <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> activation was much higher in patients with <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b than in patients with both <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>c<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b and antibodies to <jats:styled-content style=\"fixed-case\">HB<\/jats:styled-content>s<jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>b group. Antiviral prophylactic therapy could significantly reduce the risk of <jats:styled-content style=\"fixed-case\">HBV<\/jats:styled-content> reactivation.<\/jats:p>","DOI":"10.1111\/jvh.12087","type":"journal-article","created":{"date-parts":[[2013,6,3]],"date-time":"2013-06-03T13:49:42Z","timestamp":1370267382000},"page":"645-649","source":"Crossref","is-referenced-by-count":8,"title":["The effects of nucleoside analogue prophylactic treatment on <scp>HBV<\/scp> activation in <scp>HB<\/scp>c<scp>A<\/scp>b+ patients undergoing immunosuppressive therapy"],"prefix":"10.1111","volume":"20","author":[{"given":"H.\u2010L.","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases The First Affiliated Hospital of Chongqing Medical University Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The First Affiliated Hospital of Chongqing Medical University Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The First Affiliated Hospital of Chongqing Medical University Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.\u2010F.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The First Affiliated Hospital of Chongqing Medical University Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology The Second Affiliated Hospital of Nanhua University Hengyang China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The First Affiliated Hospital of Chongqing Medical University Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The First Affiliated Hospital of Chongqing Medical University Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.\u2010M.","family":"Chen","sequence":"additional","affiliation":[{"name":"Toronto General Research Institute University of Toronto Toronto ON Canada"},{"name":"Institute of Blood Transfusion Chinese Academy of Medical Sciences and Peking Union Medical College Chengdu China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.\u2010Z.","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases The First Affiliated Hospital of Chongqing Medical University Chongqing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,6,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.01.018"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.22199"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.06.027"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24551"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.023"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197806222982502"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090436"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22106"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24742"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12087","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.12087","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.12087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T08:06:56Z","timestamp":1696234016000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.12087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,3]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/jvh.12087"],"URL":"https:\/\/doi.org\/10.1111\/jvh.12087","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,3]]}}}